Medical Cannabis and Telemedicine: Why Medical Autonomy and Clear Rules Matter

Telemedicine as part of modern healthcare 

Digital consultations are now firmly embedded in healthcare delivery. Video appointments and telephone consultations complement in-person care and can significantly improve access to treatment, particularly in underserved or rural areas. Similar digital models are already common for a range of other prescription medicines, including treatments related to men’s health or obesity. The regulatory question therefore goes beyond medical cannabis and reflects a broader shift toward digital healthcare services. 

Medical autonomy as the guiding principle 

Regardless of the format of consultation, one fundamental principle must remain central: clinical decision-making lies with the treating physician. This includes not only deciding which medication is appropriate, but also determining the most suitable form of interaction with the patient. Whether a physical examination is required, a phone call for a dosage adjustment is sufficient, or a video consultation is appropriate should remain a matter of professional judgment. With that discretion comes full responsibility, independent of the communication channel used. 

Clear guardrails for digital care models 

For digital prescribing models to function responsibly, clear regulatory guardrails are essential. This includes reliable patient identification in telemedical consultations as well as transparent and well-documented treatment processes. It also requires consistent enforcement of existing legal frameworks – such as Germany’s Act on the Advertising of Medicinal Products (Heilmittelwerbegesetz, HWG) – to ensure that prescribing decisions are not influenced by improper marketing or commercial incentives. At the same time, patients’ freedom to choose their pharmacy should remain protected, and a clear structural separation between medical prescribing and commercial distribution interests across the supply chain should be maintained. 

A balanced regulatory approach 

The ongoing discussion around telemedicine in the cannabis sector reflects a broader transformation in healthcare delivery. As digital care models continue to evolve, regulation should remain technology-neutral while keeping medical responsibility at its core. Telemedicine is neither a cure-all nor a structural risk in itself. The real task is to ensure high standards of care and patient protection while allowing modern forms of healthcare delivery to develop responsibly. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,